[go: up one dir, main page]

MX2018012609A - Compuestos heterociclicos como inhibidores de la cinasa ret. - Google Patents

Compuestos heterociclicos como inhibidores de la cinasa ret.

Info

Publication number
MX2018012609A
MX2018012609A MX2018012609A MX2018012609A MX2018012609A MX 2018012609 A MX2018012609 A MX 2018012609A MX 2018012609 A MX2018012609 A MX 2018012609A MX 2018012609 A MX2018012609 A MX 2018012609A MX 2018012609 A MX2018012609 A MX 2018012609A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
ret kinase
heterocyclic compounds
formula
compounds
Prior art date
Application number
MX2018012609A
Other languages
English (en)
Other versions
MX387394B (es
Inventor
Waszkowycz Bohdan
Hynd George
Mark Sutton Jonathan
Jordan Allan
Newton Rebecca
Paoletta Silvia
Alexander Fraser Fordyce Euan
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of MX2018012609A publication Critical patent/MX2018012609A/es
Publication of MX387394B publication Critical patent/MX387394B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmula I que funcionan como inhibidores de la actividad de encima cinasa de RET (reorganizado durante la transfección): (ver formula). Fórmula I donde HET, los enlaces a, b, c y d, X,, X2, X3, X., R2 y R3 son cada uno como se definen en la presente. La presente invención también se refiere a procesos para la preparación de estos compuestos, a composiciones farmacéuticas que los comprenden, y a su uso en el tratamiento de trastornos proliferativos, tales como el cáncer, así como otras enfermedades o afecciones en las que está involucrada la actividad de cinasa de RET.
MX2018012609A 2016-04-15 2017-04-18 Compuestos heterociclicos como inhibidores de la cinasa ret. MX387394B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201606631 2016-04-15
GB201619277 2016-11-14
PCT/GB2017/051076 WO2017178844A1 (en) 2016-04-15 2017-04-18 Heterocyclic compounds as ret kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2018012609A true MX2018012609A (es) 2019-08-01
MX387394B MX387394B (es) 2025-03-18

Family

ID=58633035

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012609A MX387394B (es) 2016-04-15 2017-04-18 Compuestos heterociclicos como inhibidores de la cinasa ret.
MX2021013110A MX2021013110A (es) 2016-04-15 2018-10-15 Compuestos heterociclicos como inhibidores de la cinasa ret.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021013110A MX2021013110A (es) 2016-04-15 2018-10-15 Compuestos heterociclicos como inhibidores de la cinasa ret.

Country Status (24)

Country Link
US (4) US10954241B2 (es)
EP (2) EP3960180A1 (es)
JP (3) JP6943876B2 (es)
KR (3) KR102706837B1 (es)
CN (2) CN115650985B (es)
AU (3) AU2017250448C1 (es)
BR (2) BR112018071097B1 (es)
CA (1) CA3020778A1 (es)
CY (1) CY1124478T1 (es)
DK (1) DK3442980T3 (es)
ES (1) ES2886587T3 (es)
HR (1) HRP20211362T1 (es)
HU (1) HUE056135T2 (es)
IL (3) IL297192A (es)
LT (1) LT3442980T (es)
MX (2) MX387394B (es)
PL (1) PL3442980T3 (es)
PT (1) PT3442980T (es)
RS (1) RS62322B1 (es)
RU (1) RU2742115C2 (es)
SG (2) SG10201911665UA (es)
SI (1) SI3442980T1 (es)
SM (1) SMT202100538T1 (es)
WO (1) WO2017178844A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012013467A (es) 2010-05-20 2013-04-29 Array Biopharma Inc Compuestos macrociclicos como inhibidores de trk cinasa.
WO2017011776A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
PT3442535T (pt) 2016-04-15 2022-09-05 Cancer Research Tech Ltd Compostos heterocíclicos como inibidores da ret quinase
HUE056135T2 (hu) 2016-04-15 2022-01-28 Cancer Research Tech Ltd RET kináz inhibitor heterociklusos vegyületek
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
ES2970041T3 (es) 2018-04-03 2024-05-24 Blueprint Medicines Corp Inhibidor de RET para su uso en el tratamiento del cáncer que tiene una alteración de RET
US11873303B2 (en) 2018-04-05 2024-01-16 Merck Patent Gmbh Substituted pyrazoles as type II IRAK inhibitors
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
US12297197B2 (en) * 2019-04-03 2025-05-13 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory Pyrazolopyridine compound as RET inhibitor and application thereof
KR20220042293A (ko) * 2019-08-05 2022-04-05 베이징 즈지엔진루이 셩우이야오 커지 요우시엔공스 질소 함유 다환 축합 고리계 화합물, 이의 약학 조성물, 제조 방법 및 용도
EP4089082B1 (en) * 2020-02-20 2025-12-24 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory Quinoline compounds
EP4146654A1 (en) * 2020-05-07 2023-03-15 Adorx therapeutics Limited Antagonists of the adenosine a2a receptor
BR112022024382A2 (pt) 2020-05-29 2023-05-02 Blueprint Medicines Corp Formas sólidas de pralsetinibe
CN113214294A (zh) * 2020-06-10 2021-08-06 深圳铂立健医药有限公司 三环化合物、药物组合物及其应用
IL301739A (en) 2020-10-05 2023-05-01 Enliven Therapeutics Inc 5- and 6-Azaindole compounds for inhibition of BCR-ABL tyrosine kinases
WO2022140325A1 (en) * 2020-12-22 2022-06-30 Gilead Sciences, Inc. 6-substituted indole compounds
TWI838670B (zh) * 2020-12-22 2024-04-11 美商基利科學股份有限公司 經取代之吲哚化合物
PE20240919A1 (es) 2021-04-16 2024-04-30 Gilead Sciences Inc Compuestos de tienopirrol
CN113248518B (zh) * 2021-06-21 2022-03-25 山东大学 嘧啶哌嗪类衍生物及其制备方法与应用
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
WO2023064843A1 (en) 2021-10-15 2023-04-20 Stemline Therapeutics, Inc. Inhibitors of mutant ret kinases for use in treating cancer
CN120826229A (zh) * 2023-01-09 2025-10-21 佛罗里达大学研究基金会 Pparg调节剂
KR20250023311A (ko) * 2023-08-09 2025-02-18 주식회사 대웅제약 신규한 화합물, 및 이를 포함하는 암 또는 종양의 예방 또는 치료용 약학적 조성물

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322779A3 (en) 1987-12-29 1991-05-08 Yoshitomi Pharmaceutical Industries, Ltd. Benzolactam compounds and pharmaceutical uses thereof
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6383790B1 (en) * 1999-01-11 2002-05-07 Princeton University High affinity protein kinase inhibitors
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
EP1853261B1 (de) 2005-03-03 2017-01-11 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
CN101316845A (zh) 2005-11-17 2008-12-03 Osi医药有限公司 稠合双环mTOR抑制剂
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
CN101389630A (zh) 2005-12-29 2009-03-18 艾博特公司 蛋白激酶抑制剂
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JP2008063278A (ja) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd １−ピリジン−４−イル−インドール類の製造方法
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
EP2178563A2 (en) * 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5869222B2 (ja) 2008-01-04 2016-02-24 インテリカイン， エルエルシー 特定の化学的実体、組成物および方法
WO2009114870A2 (en) * 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
BRPI0915231A2 (pt) * 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
RS56432B1 (sr) 2009-11-05 2018-01-31 Rhizen Pharmaceuticals S A Novi benzopiran modulatori kinaze
US9765037B2 (en) 2010-01-28 2017-09-19 University Of Washington Through Its Center For Commercialization Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
EP2528919B1 (en) 2010-01-28 2016-11-02 University of Washington Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
UY33288A (es) * 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2012006619A2 (en) 2010-07-09 2012-01-12 Northeastern University ANTIPARASITIC AGENTS BASED ON mTOR INHIBITORS
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
WO2012151562A1 (en) 2011-05-04 2012-11-08 Intellikine, Llc Combination pharmaceutical compositions and uses thereof
CA2844507A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag Jak pi3k/mtor combination therapy
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
CA2854926A1 (en) 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2014047662A2 (en) 2012-09-24 2014-03-27 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
GB201217285D0 (en) 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CA2907726A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
WO2015058084A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
WO2015069441A1 (en) 2013-10-18 2015-05-14 Medivation Technologies, Inc. Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
GB201321146D0 (en) * 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
WO2016075224A1 (en) 2014-11-14 2016-05-19 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
US10350211B2 (en) 2015-01-26 2019-07-16 University Of Washington Bumped kinase inhibitor compositions and methods for treating cancer
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
US10611766B2 (en) * 2015-09-16 2020-04-07 Loxo Oncology Inc. Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
US20190077856A1 (en) 2016-03-15 2019-03-14 Memorial Sloan Kettering Cancer Center Method of treating diseases using kinase modulators
PT3442535T (pt) * 2016-04-15 2022-09-05 Cancer Research Tech Ltd Compostos heterocíclicos como inibidores da ret quinase
HUE056135T2 (hu) 2016-04-15 2022-01-28 Cancer Research Tech Ltd RET kináz inhibitor heterociklusos vegyületek

Also Published As

Publication number Publication date
KR20240142568A (ko) 2024-09-30
IL262185A (en) 2018-11-29
MX387394B (es) 2025-03-18
CN109195972B (zh) 2022-10-28
JP6943876B2 (ja) 2021-10-06
AU2022203916A1 (en) 2022-06-23
JP2021193108A (ja) 2021-12-23
SG11201808878UA (en) 2018-11-29
IL289793B (en) 2022-11-01
EP3960180A1 (en) 2022-03-02
PT3442980T (pt) 2021-09-13
RU2018138471A3 (es) 2020-05-15
CY1124478T1 (el) 2022-07-22
US11548896B2 (en) 2023-01-10
SMT202100538T1 (it) 2021-11-12
BR112018071097A2 (pt) 2019-01-29
IL297192A (en) 2022-12-01
AU2017250448A1 (en) 2018-11-01
WO2017178844A1 (en) 2017-10-19
US20190106425A1 (en) 2019-04-11
KR20180134983A (ko) 2018-12-19
IL262185B (en) 2022-02-01
CN109195972A (zh) 2019-01-11
AU2020220079B2 (en) 2022-04-21
JP2019515903A (ja) 2019-06-13
JP2023159230A (ja) 2023-10-31
IL289793B2 (en) 2023-03-01
MX2021013110A (es) 2021-11-17
SI3442980T1 (sl) 2021-11-30
KR20220054894A (ko) 2022-05-03
EP3442980B1 (en) 2021-06-09
LT3442980T (lt) 2021-09-27
RU2742115C2 (ru) 2021-02-02
BR112018071097B1 (pt) 2024-02-20
RU2018138471A (ru) 2020-05-15
CN115650985A (zh) 2023-01-31
AU2017250448B2 (en) 2020-05-21
US10954241B2 (en) 2021-03-23
KR102706837B1 (ko) 2024-09-19
AU2020220079A1 (en) 2020-09-03
US20230339954A1 (en) 2023-10-26
EP3442980A1 (en) 2019-02-20
AU2017250448C1 (en) 2021-01-07
HUE056135T2 (hu) 2022-01-28
CA3020778A1 (en) 2017-10-19
US20210155628A1 (en) 2021-05-27
HRP20211362T1 (hr) 2021-11-26
IL289793A (en) 2022-03-01
ES2886587T3 (es) 2021-12-20
RS62322B1 (sr) 2021-10-29
SG10201911665UA (en) 2020-01-30
KR102390578B1 (ko) 2022-04-26
DK3442980T3 (da) 2021-08-30
PL3442980T3 (pl) 2021-12-06
NZ747678A (en) 2024-05-31
CN115650985B (zh) 2024-08-02
US20250236624A1 (en) 2025-07-24
BR122023026297A2 (pt) 2024-01-16

Similar Documents

Publication Publication Date Title
MX2018012609A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
MX382607B (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa.
MX2017007976A (es) Compuestos inhibidores de parg.
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX2020011774A (es) Compuestos de naftiridina como inhibidores de quinasa jak.
CO2017011851A2 (es) Compuestos novedosos
CR20190156A (es) Derivados de bipirazol como inhibidores jak
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
MX2017004129A (es) Derivado de acido 4-(4-(4-fenilureido-naftalen-1-il)oxi-piridin-2- il)amino-benzoico como inhibidor de quinasa p38.
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
CR20150490A (es) Derivados de piridina como inhibidores de la quinasa reorganizada durante la transfección (ret)
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
MX377305B (es) DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2.
MX389256B (es) Compuestos heterociclicos y usos de los mismos.
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
BR112017002942A2 (pt) compostos e derivados de espiro[3h-indol-3,2´-pirrolidin]2(1h)-ona como inibidores de mdm2-p53
CL2019000476A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
PE20160689A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
ECSP16074478A (es) Compuestos novedosos
DOP2017000209A (es) Derivados de heteroarilo bicíclico fusionados con actividad como inhibidores de phd
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
CO7131369A2 (es) 5-amino[1,4]tiazinas como inhibidores de bace1